CAJ | 학술논문

目的探讨血必净在大样本研究中对重症肺炎的影响.方法采用前瞻性、随机、对照、多中心的原则,将2010年9月至2011年10月符合重症肺炎诊断的病例424例纳入研究,其中301例使用了血必净注射液,123例为对照组.治疗组静滴血必净7～14 d,所有病例均常规使用抗生素治疗,观察住院期间病死率.结果研究发现血必净治疗组的病死率为18.94％,而对照组病死率为34.15％,两组比较差异有统计学意义(P＜0.01).同时,血必净治疗组机械通气时间缩短7d,抗生素使用时间缩短1d.肺损伤评分和多器官功能障碍综合征评分的差值在使用血必净治疗后也有明显改善.实验室检查发现血必净治疗组血浆C反应蛋白的下降值较对照组的下降值更为显著.观察期间未发现血必净治疗组有明显副作用,包括过敏、出血等.结论血必净注射液合并基础治疗可以明显降低重症肺炎的病死率,减少机械通气时间和抗生素使用时间,改善肺损伤和多器官功能障碍综合征.血必净注射液在重症肺炎的治疗中是安全、有效的.
목적 탐토혈필정재대양본연구중대중증폐염적영향.방법 채용전첨성、수궤、대조、다중심적원칙,장2010년9월지2011년10월부합중증폐염진단적병례424례납입연구,기중301례사용료혈필정주사액,123례위대조조.치료조정적혈필정7～14 d,소유병례균상규사용항생소치료,관찰주원기간병사솔.결과 연구발현혈필정치료조적병사솔위18.94％,이대조조병사솔위34.15％,량조비교차이유통계학의의(P＜0.01).동시,혈필정치료조궤계통기시간축단7d,항생소사용시간축단1d.폐손상평분화다기관공능장애종합정평분적차치재사용혈필정치료후야유명현개선.실험실검사발현혈필정치료조혈장C반응단백적하강치교대조조적하강치경위현저.관찰기간미발현혈필정치료조유명현부작용,포괄과민、출혈등.결론 혈필정주사액합병기출치료가이명현강저중증폐염적병사솔,감소궤계통기시간화항생소사용시간,개선폐손상화다기관공능장애종합정.혈필정주사액재중증폐염적치료중시안전、유효적.
Objective To investigate the effects of Xuebijing in severe pneumonia in a large cohort population.Methods Prospective,multiple center randomized control study.Patients who met criteria of severe pneumonia was enrolled and assigned as control and treatment group randomly.In treatment group,Xuebijing was infused for 7-14 days.Standard clinical treatment with antibiotics was applied in all patients.Mortality and morbidity was followed during hospitalization.Results Mortality analysis showed reduced mortality in Xuebijing group compared to control group (18.94 ％ vs 34.15％,P ＜ 0.01).Treatment with Xuebijing was also associated with reduced ventilation days and antibiotic use days.No significant complications associated with Xuebijing were found during study.Conclusions Adjunct therapy with Xuebijing significantly reduces mortality and morbidity in severe pneumonia patients.Xuebijing is recommended as combination therapy in severe pneumonia in future.